Most importantly, this further highlights that the addition of the ApoE tandem peptide to IDS is required to provide a full correction of the neurocognitive aspect in MPS II mice, although a much higher VCN in LV.IDS‐treated mice might achieve the same effect. The gene discussed is APOE; the disease is mucopolysaccharidosis type 2.